Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancerXuexia Tong(Shimane University), Takeshi Isobe(Shimane University)Respiratory ResearchDecember 1, 201910.1186/s12931-019-1244-2Cited by 50SaveCiteExport RISWatch citationsRelated PapersNovel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer|Oncotarget|2018|32